Subpotent Blood Pressure Drug Recalled

Glenmark Pharmaceuticals Inc. is recalling 1200 bottles of trandolapril and verapamil hydrochloride extended-release tablets for subpotency. According to the August 30, 2023, US Food and Drug Administration (FDA) Enforcement Report, samples tested out-of-specification at the 3-month time point.

The recall affects trandolapril and verapamil hydrochloride extended-release tablets, 2 mg/180 mg, in 100-count bottles (NDC 68462-295-01) from batch 19224744. The tablets were manufactured by Glenmark Pharmaceuticals Ltd., Goa, India, for Glenmark Pharmaceuticals Inc., Mahwah, New Jersey, and distributed throughout the United States.

Glenmark Pharmaceuticals Inc. voluntarily initiated the recall August 14, 2023. The FDA designated the recall Class III on August 22, 2023. Per the recall classification, use of the affected tablets is not likely to cause harm.

Combination trandolapril and verapamil is a prescription drug used to treat patients with high blood pressure.